InterventionsHuman trial

Impact of Once-Weekly Injectable Semaglutide vs. Placebo on Fatty Liver Index Scores in People with Overweight/Obesity: A Post Hoc Analysis (STEP1)

ADA Scientific Sessions 2026 Abstract

The paper

Gema Frühbeck, Maximilian Jara, Naveen Rathor, Jonathan Sudkamp, Lauren Wilson

Pamplona

ADA Scientific Sessions 2026 Abstract · 5 Jun 2026

Presented at ADA Scientific Sessions 2026 · Poster 2592-P

doi.org/10.2337/db26-2592-p

Survodutide reduces weight in adults with diabetes and obesity
The New England Journal of Medicine · 4 Oct 2026
Fatty liver linked to progression of obesity in adults
Frontiers in Nutrition · 7 Oct 2026
Semaglutide may protect kidneys by reducing vascular resistance
Nature Medicine · 4 Oct 2026
A triple-target drug cut body weight by up to 19.7% in a trial
Cell Metabolism · 8 Oct 2026